Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 3:20 p.m. ET. The event will be held virtually, and a live webcast of the presentation can be accessed on Acadia's website, with an archived recording available until December 15, 2020. Acadia specializes in neuroscience, having developed the first therapy for hallucinations and delusions related to Parkinson’s disease psychosis, and is involved in various research areas including dementia-related psychosis and schizophrenia.
- None.
- None.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020, at 3:20 p.m. Eastern Time.
The conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through December 15, 2020.
About Acadia Pharmaceuticals
Acadia is trailblazing breakthroughs in neuroscience to elevate life through science. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.
